Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 276
- Registration Number
- NCT01364012
- Locations
- 🇨🇳
Beijing Hospital of Ministry of Health; Hematology, Beijing, China
🇨🇳General Hospital of Chinese PLA; Department of Hematology, Beijing, China
🇨🇳Beijing Chest Hospital; Oncology Department, Beijing, China
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT01362062
- Locations
- 🇮🇳
Excel Center, Guwahati, India
🇮🇳Sir Gangaram Hospital, New Delhi, Delhi, India
🇮🇳Healing Touch City Clinic, Chandigarh, India
A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: RO5429083
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT01358903
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
Phase 3
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4804
- Registration Number
- NCT01358877
- Locations
- 🇺🇸
Texas Oncology - DFW, Dallas, Texas, United States
🇺🇸The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: PlaceboDrug: RO6807952
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT01358929
An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 156
- Registration Number
- NCT01358942
A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO4917838
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT01356550
A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)
Completed
- Conditions
- Anemia
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1288
- Registration Number
- NCT01356589
- Locations
- 🇬🇷
Ahepa Hospital; 1St Dept. of Medicine, Thessaloniki, Greece
🇬🇷Kyanous Stavros of Patras, Renal Disease Therapy Unit, Patra, Greece
🇬🇷General Hospital Tzanio ; Nephrology, Piraeus, Greece
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 39
- Registration Number
- NCT01353859
An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma
Completed
- Conditions
- Renal Cell Cancer
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT01351571
© Copyright 2025. All Rights Reserved by MedPath